Ardena has successfully finalized the divestment of its active pharmaceutical ingredient (API) facility in Södertälje, Sweden, to Nanologica AB. Following the completion of the transaction, the site will operate as a wholly-owned subsidiary of the Nanologica Group and revert to its original name, Syntagon AB.
Facility Capabilities and Transaction Details:
-
Manufacturing Expertise: The Södertälje facility is a well-established CDMO specializing in small-molecule APIs. Recent significant investments in chromatographic purification and falling film distillation have enhanced its ability to support programs from early-stage development through clinical and commercial manufacturing.
-
Strategic Partnership: Ardena has transitioned into a shareholder of Nanologica, maintaining a long-standing collaborative relationship. An ongoing service agreement ensures that Ardena remains a key customer of the site, facilitating the continuous development of precision medicines and complex therapies.
-
Governance Alignment: As part of the deal, Ardena CEO Jeremie Trochu will join the Nanologica Board of Directors to oversee strategic alignment between the two organizations.
Ardena’s Expansion Strategy: The divestment allows Ardena to sharpen its focus on integrated drug development, nanomedicine, and bioanalysis. The company continues its growth trajectory elsewhere, notably following its February 2025 acquisition of a drug product manufacturing site in Somerset, New Jersey, which includes the establishment of a new bioanalytical laboratory.